ABSTRACT
Lambda interferons (IFNL, IFN-λ) are pro-inflammatory cytokines important in acute and chronic viral infection. Single-nucleotide polymorphisms rs12979860 and rs8099917 within the IFNL gene locus predict hepatitis C virus (HCV) clearance, as well as inflammation and fibrosis progression in viral and non-viral liver disease. The underlying mechanism, however, is not defined. Here we show that the rs12979860 CC genotype correlates with increased hepatic metallothionein expression through increased systemic zinc levels. Zinc interferes with IFN-λ3 binding to IFNL receptor 1 (IFNLR1), resulting in decreased antiviral activity and increased viral replication (HCV, influenza) in vitro. HCV patients with high zinc levels have low hepatocyte antiviral and inflammatory gene expression and high viral loads, confirming the inhibitory role of zinc in vivo. We provide the first evidence that zinc can act as a potent and specific inhibitor of IFN-λ3 signalling and highlight its potential as a target of therapeutic intervention for IFN-λ3-mediated chronic disease.
Subject(s)
Interleukins/metabolism , Signal Transduction , Zinc/metabolism , Adult , Antiviral Agents/pharmacology , Cell Line, Tumor , Chemokines/metabolism , Female , Gene Expression Regulation/drug effects , Genotype , Hepatitis C/genetics , Humans , Inflammation/genetics , Inflammation/pathology , Inflammation Mediators/metabolism , Interferon-alpha/pharmacology , Interferons , Interleukins/genetics , Interleukins/pharmacology , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver/virology , Male , Metallothionein/genetics , Metallothionein/metabolism , Middle Aged , Models, Biological , Molecular Sequence Annotation , Receptors, Cytokine/metabolism , Receptors, Interferon , Signal Transduction/drug effects , Transcription, Genetic/drug effects , Transcriptome/genetics , Zinc/bloodABSTRACT
Treatment of chronic hepatitis C virus (HCV) infection is evolving rapidly with the development of novel direct acting antivirals (DAAs), however viral clearance remains intimately linked to the hepatic innate immune system. Patients demonstrating a high baseline activation of interferon stimulated genes (ISGs), termed interferon refractoriness, are less likely to mount a strong antiviral response and achieve viral clearance when placed on treatment. As a result, suppressor of cytokine signalling (SOCS) 3 and other regulators of the IFN response have been identified as key candidates for the IFN refractory phenotype due to their regulatory role on the IFN response. AXL is a receptor tyrosine kinase that has been identified as a key regulator of interferon (IFN) signalling in myeloid cells of the immune system, but has not been examined in the context of chronic HCV infection. Here, we show that AXL is up-regulated following HCV infection, both in vitro and in vivo and is likely induced by type I/III IFNs and inflammatory signalling pathways. AXL inhibited type IFNα mediated ISG expression resulting in a decrease in its antiviral efficacy against HCV in vitro. Furthermore, patients possessing the favourable IFNL3 rs12979860 genotype associated with treatment response, showed lower AXL expression in the liver and a stronger induction of AXL in the blood, following their first dose of IFN. Together, these data suggest that elevated AXL expression in the liver may mediate an IFN-refractory phenotype characteristic of patients possessing the unfavourable rs12979860 genotype, which is associated with lower rates of viral clearance.
Subject(s)
Gene Expression Regulation, Enzymologic , Hepacivirus/metabolism , Hepatitis C, Chronic/metabolism , Interferon-alpha/metabolism , Liver/metabolism , Proto-Oncogene Proteins/biosynthesis , Receptor Protein-Tyrosine Kinases/biosynthesis , Female , Hep G2 Cells , Hepacivirus/genetics , Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/pathology , Humans , Interferon-alpha/genetics , Interferons , Interleukins/genetics , Interleukins/metabolism , Liver/pathology , Male , Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , Signal Transduction/genetics , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins/genetics , Suppressor of Cytokine Signaling Proteins/metabolism , Axl Receptor Tyrosine KinaseABSTRACT
Recently, single nucleotide polymorphisms, in the vicinity of the interferon lambda 3 (IFNL3) gene have been identified as the strongest predictor of spontaneous and treatment induced clearance of hepatitis C virus (HCV) infection. Since then, increasing evidence has implicated the innate immune response in mediating the IFNL3 genotype effect. Dendritic cells (DCs) are key to the host immune response in HCV infection and their vital role in the IFNL3 genotype effect is emerging. Reports have identified subclasses of DCs, particularly myeloid DC2s and potentially plasmacytoid DCs as the major producers of IFNL3 in the setting of HCV infection. Given the complexities of dendritic cell biology and the conflicting current available data, this review aims to summarize what is currently known regarding the role of dendritic cells in HCV infection and to place it into context of what is know about lambda interferons and dendritic cells in general.
Subject(s)
Dendritic Cells/immunology , Hepacivirus/immunology , Hepatitis C/genetics , Hepatitis C/immunology , Immunity, Innate/genetics , Interleukins/genetics , Interleukins/immunology , Animals , Dendritic Cells/metabolism , Dendritic Cells/virology , Genotype , Hepacivirus/metabolism , Hepacivirus/pathogenicity , Hepatitis C/diagnosis , Hepatitis C/metabolism , Hepatitis C/virology , Host-Pathogen Interactions , Humans , Interferons , Interleukins/metabolism , Polymorphism, Single Nucleotide , Signal TransductionABSTRACT
Genome-wide association studies have identified a linkage disequilibrium (LD) block on chromosome 12 associated with multiple sclerosis (MS), type 1 diabetes and other autoimmune diseases. This block contains CYP27B1, which catalyzes the conversion of 25 vitamin D3 (VitD3) to 1,25VitD3. Fine-mapping analysis has failed to identify which of the 17 genes in this block is most associated with MS. We have previously used a functional approach to identify the causal gene. We showed that the expression of several genes in this block in whole blood is highly associated with the MS risk allele, but not CYP27B1. Here, we show that CYP27B1 is predominantly expressed in dendritic cells (DCs). Its expression in these cells is necessary for their response to VitD, which is known to upregulate pathways involved in generating a tolerogenic DC phenotype. Here, we utilize a differentiation protocol to generate inflammatory (DC1) and tolerogenic (DC2) DCs, and show that for the MS risk allele CYP27B1 is underexpressed in DCs, especially DC2s. Of the other Chr12 LD block genes expressed in these cells, only METT21B expression was as affected by the genotype. Another gene associated with autoimmune diseases, CYP24A1, catabolizes 1,25 VitD3, and is predominantly expressed in DCs, but equally between DC1s and DC2s. Overall, these data are consistent with the hypothesis that reduced VitD pathway gene upregulation in DC2s of carriers of the risk haplotype of CYP27B1 contributes to autoimmune diseases. These data support therapeutic approaches aimed at targeting VitD effects on DCs.
Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , Chromosomes, Human, Pair 12 , Dendritic Cells/immunology , Multiple Sclerosis/genetics , Vitamin D/metabolism , Adult , Aged , Dendritic Cells/metabolism , Dendritic Cells/pathology , Female , Gene Expression Regulation , Genetic Linkage , Genetic Predisposition to Disease , Genetic Variation , Humans , Male , Middle Aged , Multiple Sclerosis/epidemiology , Signal TransductionABSTRACT
Common IFN lambda 3 (IFNL3) variants have been demonstrated to affect spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection. The functional basis of these genetic variants has yet to be determined. Data examining the effect of IFNL3, specifically, in innate immune cells is lacking. Here, we determined the expression of IFNL3 and its receptor IFNLR1 in blood immune cell subsets and in HCV-infected livers. Next we assessed their sensitivity to IFNL3. All participants were genotyped for the IFNL3 SNPs rs8099917 and rs12979860. Importantly, unstimulated blood immune cells express significantly higher levels of IFNL3 than HCV liver biopsies. Plasmacytoid dendritic cells (pDCs) are the predominant producers of IFNLR1, especially in response to IFN-α. PBMCs, monocytes and pDCs all respond to IFNL3 based on MxA up-regulation. No differences in IFNL3 expression levels between rs8099917 or rs12979860 genotypes were detected. This is the first study to show peripheral blood pDCs to be the main producers of IFNL3, especially compared with HCV-infected livers. This makes innate immune cells the key players in determining the functional significance of INFL3 polymorphisms in patients with HCV.
Subject(s)
Hepacivirus/pathogenicity , Hepatitis C/pathology , Hepatitis C/virology , Immunity, Cellular/physiology , Immunity, Innate/physiology , Interleukins/physiology , Antiviral Agents/pharmacology , Cohort Studies , Dendritic Cells/immunology , Genotype , Hepacivirus/genetics , Hepatitis C/genetics , Humans , Interferon-alpha/pharmacology , Interferons , Interleukins/genetics , Interleukins/immunology , Liver/pathology , Liver/virology , Receptors, Cytokine/genetics , Receptors, Cytokine/immunology , Receptors, Cytokine/physiology , Receptors, InterferonABSTRACT
BACKGROUND: To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-alpha and ribavirin (PegIFN/R). Viral clearance is achieved in 40%-50% of patients. Interleukin 28B (IL28B) genotype predicts treatment-induced and spontaneous clearance. To improve the predictive value of this genotype, we studied the combined effect of variants of IL28B with human leukocyte antigen C (HLA-C), and its ligands the killer immunoglobulin-like receptors (KIR), which have previously been implicated in HCV viral control. METHODS AND FINDINGS: We genotyped chronic hepatitis C (CHC) genotype 1 patients with PegIFN/R treatment-induced clearance (nâ=â417) and treatment failure (nâ=â493), and 234 individuals with spontaneous clearance, for HLA-C C1 versus C2, presence of inhibitory and activating KIR genes, and two IL28B SNPs, rs8099917 and rs12979860. All individuals were Europeans or of European descent. IL28B SNP rs8099917 "G" was associated with absence of treatment-induced clearance (odds ratio [OR] 2.19, pâ=â1.27×10(-8), 1.67-2.88) and absence of spontaneous clearance (OR 3.83, pâ=â1.71×10(-14), 2.67-5.48) of HCV, as was rs12979860, with slightly lower ORs. The HLA-C C2C2 genotype was also over-represented in patients who failed treatment (OR 1.52, pâ=â0.024, 1.05-2.20), but was not associated with spontaneous clearance. Prediction of treatment failure improved from 66% with IL28B to 80% using both genes in this cohort (OR 3.78, pâ=â8.83×10(-6), 2.03-7.04). There was evidence that KIR2DL3 and KIR2DS2 carriage also altered HCV treatment response in combination with HLA-C and IL28B. CONCLUSIONS: Genotyping for IL28B, HLA-C, and KIR genes improves prediction of HCV treatment response. These findings support a role for natural killer (NK) cell activation in PegIFN/R treatment-induced clearance, partially mediated by IL28B.
Subject(s)
HLA-C Antigens/genetics , Hepacivirus/pathogenicity , Hepatitis C, Chronic/therapy , Interleukins/genetics , Adult , Alleles , Antiviral Agents/therapeutic use , Case-Control Studies , Cohort Studies , Cross-Sectional Studies , Drug Therapy, Combination , Female , Genotype , Hepacivirus/immunology , Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/virology , Humans , Interferon-alpha/therapeutic use , Interferons , Killer Cells, Natural/immunology , Male , Middle Aged , Odds Ratio , Pharmacogenetics/methods , Polymorphism, Single Nucleotide , Predictive Value of Tests , RNA, Viral/analysis , Receptors, KIR/genetics , Receptors, KIR2DL3/genetics , Ribavirin/therapeutic use , Treatment Outcome , Viral Load , White PeopleABSTRACT
Drug-induced hypersensitivity syndrome (DIHS) is a rare and potentially fatal reaction characterized by fever, rash, and internal organ involvement that typically occurs between 3 and 6 weeks after commencing the drug. We describe such a case in a 26-year-old woman, who developed fever, exfoliative erythroderma, facial edema, cervical lymphadenopathy, hepatitis, and leukocytosis 6 weeks after commencing carbamazepine for lower back pain. Her serum angiotensin-converting enzyme level was also raised to 144 U/L (8-52 U/L). Skin biopsies demonstrated an unusual superficial dermal perivascular inflammatory infiltrate, which included conspicuous granulomas mixed with moderate numbers of lymphocytes. Eosinophils were not a feature. Her carbamazepine was withdrawn, and oral prednisone was commenced initially at a dose of 1 mg.kg.d and slowly weaned over a 6-week period. Her fever, rash, facial edema, and hepatitis gradually resolved within this period, and her serum angiotensin-converting enzyme level returned to within the normal range. Although the patient's clinical course was consistent with a DIHS, it was accompanied by a previously unreported finding of a superficial granulomatous dermatitis. Granuloma formation as a sequel to medication use is a feature of interstitial granulomatous drug reaction. However, interstitial granulomatous drug reaction consists of localized violaceous plaques with a predilection for skin fold areas and liver function abnormalities have not been described. Granulomatous inflammation in other organ systems, including the liver and kidney, has also been described after the use of carbamazepine, but these reactions are not associated with the systemic manifestations observed in DIHS.
Subject(s)
Analgesics/adverse effects , Carbamazepine/adverse effects , Dermatitis/etiology , Dermatitis/pathology , Drug Hypersensitivity/pathology , Granuloma/chemically induced , Adult , Anti-Inflammatory Agents/therapeutic use , Dermatitis/drug therapy , Drug Hypersensitivity/drug therapy , Female , Granuloma/pathology , Hepatitis/drug therapy , Hepatitis/etiology , Humans , Low Back Pain/drug therapy , Peptidyl-Dipeptidase A/blood , Prednisone/therapeutic useABSTRACT
Twenty-five patients living in a tick-endemic region of Sydney, New South Wales developed red meat allergy after experiencing large local reactions to tick bites. This represents a potentially novel cross-reaction between an arthropod and a food protein. (MJA 2009; 190: 510-511).